₹ 0.2 Cr
Volume transacted
4.1 K
stocks traded
Last Updated time: 26 Jul 9.00 AM
Aarti Drugs Ltd
NSE: AARTIDRUGS
PE
28.2
Last updated : 26 Jul 9.00 AM
The P/E Ratio of Aarti Drugs Ltd is 28.2 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Aarti Drugs Ltd changed from 16.8 on March 2019 to 18.8 on March 2023 . This represents a CAGR of 2.28% over 5 years. a1#The Latest Trading Price of Aarti Drugs Ltd is ₹ 525.55 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Aarti Drugs Ltd changed from ₹ 1510 crore on March 2019 to ₹ 3128 crore on March 2023 . This represents a CAGR of 15.68% over 5 years. a1#The Revenue of Aarti Drugs Ltd changed from ₹ 622.22 crore to ₹ 621.07 crore over 8 quarters. This represents a CAGR of -0.09% a1#The EBITDA of Aarti Drugs Ltd changed from ₹ 67.4 crore to ₹ 86.89 crore over 8 quarters. This represents a CAGR of 13.54% a1#The Net Pr of Aarti Drugs Ltd changed from ₹ 34.78 crore to ₹ 47.31 crore over 8 quarters. This represents a CAGR of 16.63% a1#The Dividend Payout of Aarti Drugs Ltd changed from 2.7 % on March 2019 to 6.06 % on March 2023 . This represents a CAGR of 17.55% over 5 years. a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Period | |
---|---|
Mar '19 | 16.8 |
Mar '20 | 8.3 |
Mar '21 | 23.1 |
Mar '22 | 19.4 |
Mar '23 | 18.8 |
Market Cap
₹ 4,831 Cr
EPS
₹ 18.6
P/E Ratio (TTM) *
28.2
P/B Ratio (TTM) *
3.8
Day’s High
₹ 545.55
Day’s Low
₹ 524.4
DTE *
0.4
ROE *
13.4
52 Week High
₹ 624.0
52 Week Low
₹ 430.0
ROCE *
14.6
* All values are consolidated
Last Updated time: 26 Jul 9.00 AM
* All values are consolidated
Last Updated time: 26 Jul 9.00 AM
Aarti Drugs Ltd
NSE: AARTIDRUGS
PRICE
₹ 525.55
-4.60 (-0.87%)
Last updated : 25 Jul 15:30
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
* All values are in Rupees
Strength
2
S
Weakness
1
W
Opportunity
0
O
Threats
0
T
Market Value
₹ 4,832
Asset Value
₹ 1,492
2.2 X
Value addition
* All values are in Rupees
Company Name | PE | Market Cap (INR Cr.) |
---|---|---|
Aarti Drugs Ltd | 28 | 4,831 |
Sun Pharmaceuticals Industries Ltd | 40 | 399,537 |
Zydus Lifesciences Ltd | 31 | 121,312 |
Cipla Ltd | 28 | 121,120 |
Divis Laboratories Ltd | 75 | 120,782 |
Dr Reddys Laboratories Ltd | 20 | 114,348 |
Earnings
₹171 Cr
28.2 X
PE Ratio
Market Cap
₹4831Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Earnings
₹171 Cr
28.2 X
PE Ratio
Market Cap
₹4831Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 1510 |
Mar '20 | 1179 |
Mar '21 | 6476 |
Mar '22 | 3973 |
Mar '23 | 3128 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 622 |
Sep '22 | 688 |
Dec '22 | 665 |
Mar '23 | 743 |
Jun '23 | 662 |
Sep '23 | 642 |
Dec '23 | 608 |
Mar '24 | 621 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | 67 |
Sep '22 | 74 |
Dec '22 | 72 |
Mar '23 | 94 |
Jun '23 | 85 |
Sep '23 | 77 |
Dec '23 | 72 |
Mar '24 | 87 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | 35 |
Sep '22 | 39 |
Dec '22 | 37 |
Mar '23 | 56 |
Jun '23 | 48 |
Sep '23 | 40 |
Dec '23 | 37 |
Mar '24 | 47 |
* All values are a in ₹crore
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 3 |
Mar '20 | 3 |
Mar '21 | 9 |
Mar '22 | 5 |
Mar '23 | 6 |
* All values are a in %
Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra. It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries, Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries. The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs), Steroids, Pharmaceutical Intermediates, and Specialty Chemicals, such as Benzene Sulphonyl Chloride, Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd, a part of Aarti Group of Industries, was incorporated in September 28th, 1984. In the year 1993, the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95, the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also, Rupal Chemical Industries, a group company, was amalgamated with the company. During the year 1996-97, the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01, they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03, the company expanded the production capacity of bulk drugs by 598,000 kg to 17,430,000 kg. During the year 2003-04, the company further expanded the production capacity of bulk drugs by 588,000 kg to 18,018,000 kg. During the year 2004-05, the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06, the company increased the production capacity of Pharmaceutical by 2,325,000 kg to 24,020,000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also, they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company. During the year 2006-07, the company increased the production capacity by 570,000 kg to 24,590,000 kg. During the next year, they increased the production capacity by 399,000 kg to 24,989,000 kg. During the year 2008-09, they further increased the production capacity of Pharmaceutical by 50,000 kg to 25,000,000 kg. During the year 2009-10, the company carried out process improvement work in bulk drugs, such as antihistaminic/anti-allergic, anti-inflammatory and anti-diabetic. ADL expanded the production capacity from 25,000,000 kg to 25,716,000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd., wholly owned subsidiary of the Company, with the Company became operative w.e.f. from 6th July, 2012. During year 2015, Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd., situated at Baddi, Himachal Pradesh. During year 2020, Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA, incorporated in Santiago, Chile, was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary), in Mumbai, was carrying on business of manufacturers, producers, processors, buyers, sellers, importers, exporters or otherwise dealers in Speciality and other chemicals, pharmaceutical and drugs. In 2022, the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur, which turned operational effective from May 2022.
Aarti Drugs to conduct board meeting
Aarti Drugs will hold a meeting of the Board of Directors of the Company on 26 July 2024. ...
Read more
22 Jul 202410:36
Aarti Drugs reports fire incident at one of its unit at Tarapur
Aarti Drugs announced that on 17 June 2024, at around 2:30 pm IST, fire occurred at N-198 ...
Read more
18 Jun 202414:43
Aarti Drugs reports PAT of Rs 47 cr in Q4 FY24
Revenue from operations dropped 16.48% to Rs 619.99 crore in Q4 FY24 as compared with Rs 7...
Read more
04 May 202416:39
Aarti Drugs to table results
Aarti Drugs will hold a meeting of the Board of Directors of the Company on 3 May 2024. Po...
Read more
27 Apr 202409:36
Pinnacle Life Science's Formulations (Oncology) unit completes USFDA inspection
Aarti Drugs announced that the United States Food and Drug Administration (US FDA) has ins...
Read more
23 Apr 202414:19
Aarti Drugs Baddi facility gets 5 USFDA observations
In a regulatory filing, Aarti Drugs said that the United States Food and Drug Administrati...
Read more
23 Apr 202415:25
FAQs for PE of Aarti Drugs Ltd
What is Aarti Drugs Ltd current share price?
What is Aarti Drugs Ltd's market cap?
What are Aarti Drugs Ltd's total net assets?
Is Aarti Drugs Ltd making a profit or loss?
Unlimited trading at just
Rs. 199